FibroBiologics (FBLG) Competitors $2.81 -0.27 (-8.77%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends FBLG vs. PRTC, XERS, KALV, ARCT, CTNM, AQST, ZVRA, DNA, VALN, and GHRSShould you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include PureTech Health (PRTC), Xeris Biopharma (XERS), KalVista Pharmaceuticals (KALV), Arcturus Therapeutics (ARCT), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), Zevra Therapeutics (ZVRA), Ginkgo Bioworks (DNA), Valneva (VALN), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. FibroBiologics vs. PureTech Health Xeris Biopharma KalVista Pharmaceuticals Arcturus Therapeutics Contineum Therapeutics Aquestive Therapeutics Zevra Therapeutics Ginkgo Bioworks Valneva GH Research FibroBiologics (NASDAQ:FBLG) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability. Is FBLG or PRTC more profitable? Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A N/A N/A PureTech Health N/A N/A N/A Do analysts recommend FBLG or PRTC? FibroBiologics currently has a consensus price target of $12.00, suggesting a potential upside of 312.37%. PureTech Health has a consensus price target of $45.00, suggesting a potential upside of 104.55%. Given FibroBiologics' higher probable upside, equities research analysts plainly believe FibroBiologics is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals have more ownership in FBLG or PRTC? 0.0% of PureTech Health shares are held by institutional investors. 20.8% of FibroBiologics shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer FBLG or PRTC? PureTech Health received 5 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 100.00% of users gave FibroBiologics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformFibroBiologicsOutperform Votes4100.00% Underperform VotesNo VotesPureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Does the media prefer FBLG or PRTC? In the previous week, FibroBiologics had 5 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for FibroBiologics and 3 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.81 beat FibroBiologics' score of 0.50 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, FBLG or PRTC? FibroBiologics has higher earnings, but lower revenue than PureTech Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$16.49MN/AN/APureTech Health$3.33M158.16-$65.70MN/AN/A SummaryFibroBiologics beats PureTech Health on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Click here to reserve your seat at the Crypto Community Summit. Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBLG vs. The Competition Export to ExcelMetricFibroBiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.32M$7.10B$5.34B$8.91BDividend YieldN/A8.03%4.98%4.03%P/E RatioN/A11.24135.6617.44Price / SalesN/A389.801,262.7694.87Price / CashN/A49.2238.9536.42Price / Book72.759.136.305.91Net Income-$16.49M$153.75M$118.43M$224.86M7 Day Performance-18.49%-1.25%-1.58%-0.59%1 Month Performance7.78%8.52%3.00%4.03%1 Year PerformanceN/A39.39%36.17%27.01% FibroBiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBLGFibroBiologics2.1909 of 5 stars$2.81-8.8%$12.00+327.0%N/A$98.80MN/A0.0010Analyst ForecastNews CoveragePRTCPureTech Health2.2088 of 5 stars$20.80-1.4%N/A+3.5%$497.74M$3.33M0.00100Short Interest ↑XERSXeris Biopharma4.0215 of 5 stars$3.36+0.6%N/A+94.4%$497.66M$163.91M-7.81290Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals3.952 of 5 stars$11.18-2.0%N/A+35.4%$483.20MN/A-3.17150Positive NewsARCTArcturus Therapeutics2.5047 of 5 stars$18.74+2.2%N/A+8.3%$479.92M$169.93M-7.29180Earnings ReportAnalyst RevisionGap UpCTNMContineum Therapeutics1.7592 of 5 stars$18.55+7.6%N/AN/A$477.11M$50M0.0031Short Interest ↑News CoverageAQSTAquestive Therapeutics2.0137 of 5 stars$5.08+0.2%N/A+187.5%$468.96M$50.58M-11.29160Short Interest ↓ZVRAZevra Therapeutics3.4974 of 5 stars$8.81flatN/A+109.2%$463.57M$23.69M-5.2465Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownDNAGinkgo Bioworks0.9781 of 5 stars$8.39+1.0%N/AN/A$461.83M$251.46M-0.461,218Short Interest ↓News CoverageVALNValneva2.8325 of 5 stars$5.48-2.0%N/A-62.2%$454.17M$165.52M-10.54700High Trading VolumeGHRSGH Research1.7574 of 5 stars$8.62-1.1%N/A+23.2%$448.48MN/A-12.8710Short Interest ↑News Coverage Related Companies and Tools Related Companies PRTC Competitors XERS Competitors KALV Competitors ARCT Competitors CTNM Competitors AQST Competitors ZVRA Competitors DNA Competitors VALN Competitors GHRS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FBLG) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredTrump Win = "Bull Trap"?Dan's research shows that the last time the market looked this way, not only did our economy suffer a large su...Stansberry Research | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
